SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
Drug Development
AbbVie’s Elagolix Dazzles in Phase III Trial
AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.
March 13, 2018
 · 
2 min read
 · 
Mark Terry
BioMidwest
Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market
Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.
March 2, 2018
 · 
2 min read
 · 
Mark Terry
Get Ready for the M&A Explosion
Deals
Tax Reform Could Lead to Spike in Biopharma M&A Activity
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
February 23, 2018
 · 
2 min read
 · 
Mark Terry
Business
Achillion Slashes Staff and Initiates Restructuring Following Termination of J&J Deal
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
February 22, 2018
 · 
2 min read
 · 
Alex Keown
Drug Development
AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
February 21, 2018
 · 
3 min read
Business
AbbVie and Voyager Therapeutics Launch $1.2 Billion+ Alzheimer’s Partnership
AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
February 20, 2018
 · 
3 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Bio NC
3 Biotech Gems to Stock Up on This Month
A look at a few bargains in today’s choppy market.
February 12, 2018
 · 
1 min read
Drug Development
3 Drugs That Could Make-or-Break AbbVie
A look at three drug approvals of vital importance to the company this year.
February 12, 2018
 · 
3 min read
 · 
Mark Terry
3 Biotechs That Got Huge Boosts From Spark's FDA P
BioMidwest
3 Best Biotherapeutics Stocks to Buy Right Now
Sometimes the biggest are also the best. That’s the case for biotherapeutics stocks.
February 2, 2018
 · 
1 min read
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Deals
AbbVie Declares Quarterly Dividend payable November 15, 2019
September 6, 2019
 · 
1 min read
Drug Development
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
August 29, 2019
 · 
5 min read
BioMidwest
AbbVie to Present at the Morgan Stanley Healthcare Conference
August 27, 2019
 · 
2 min read
FDA
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
August 16, 2019
 · 
14 min read
BioMidwest
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
August 5, 2019
 · 
6 min read
Genetown
Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
July 31, 2019
 · 
2 min read
Business
AbbVie Reports Second-Quarter 2019 Financial Results
July 26, 2019
 · 
25 min read
Deals
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
July 15, 2019
 · 
2 min read
Deals
AbbVie to Host Second-Quarter 2019 Earnings Conference Call
July 11, 2019
 · 
1 min read
Deals
AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director
June 27, 2019
 · 
7 min read
Load More